Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 108

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 108
---
 |
| Finance fee                                     |     |                   |          - |   |     |   |   (104,245 | ) |     |   |    104,245 |   |     |     |  (100 | )% |
| Change in fair value of derivative liabilities  |     |                   |    340,405 |   |     |   |  2,118,175 |   |     |   | (1,777,770 | ) |     |     |   (84 | )% |
| Gain on sale of marketable securities           |     |                   |    100,118 |   |     |   |      1,744 |   |     |   |     98,374 |   |     |     | 5,641 | %  |
| Change in fair value of marketable securities   |     |                   |    (71,568 | ) |     |   |     21,134 |   |     |   |    (92,702 | ) |     |     |  (439 | )% |
| Loss on settlement of convertible debt          |     |                   |   (833,501 | ) |     |   |   (477,221 | ) |     |   |   (356,280 | ) |     |     |   (75 | )% |
| Total other expense                             |     |                   | (1,627,286 | ) |     |   |   (342,665 | ) |     |   | (1,284,621 | ) |     |     |   375 | %  |
| Net loss                                        |     | $                 | (7,546,328 | ) |     | $ | (4,952,223 | ) |     | $ | (2,594,105 | ) |     |     |    52 | %  |

Research and Development.Research and development (“R&D”) expenses were $2.6 million for the nine months ended September 30, 2024, as compared to $2.8 million for nine months ended September 30, 2023. The decrease of $0.2 million, or 6%, is primarily related to the Company having completed production of the drug product in the prior period substantially offset by costs incurred for the start of work related to the initiation of trials in the current period.

| 70 |

R&D compensation related expenses were $0.9 million in the